July Update
SPOTLIGHT
"Open, collaborative approaches are needed to accelerate the science to fight long-standing and emerging health threats. By working collectively, the global health community can increase and accelerate the potential to achieve major research breakthroughs for the millions of people worldwide who suffer from devastating diseases like TB, malaria and NTDs."

Wim Parys, M.D., Global Head of Research & Development, Global Public Health 

VIDEO HIGHLIGHT

Meet the Johnson & Johnson scientists working to develop medicines and vaccines to stop infectious diseases.
DID YOU KNOW?
80,000
THE NUMBER OF COMPOUNDS IN MOLECULAR LIBRARY JANSSEN SHARED WITH PARTNERS TO
FIND NEW TREATMENTS FOR
TB, MALARIA, NTDS 1
11
THE NUMBER OF AFRICAN COUNTRIES THAT APPROVED INTELENCE 25 MG THROUGH WORLD HEALTH ORGANIZATION PILOT PROJECT WITH JANSSEN 2
2 MILLION
THE NUMBER OF EBOLA VACCINE DOSES PLEDGED BY 
JOHNSON & JOHNSON READY TO BE DEPLOYED AT ANY MOMENT TO SUPPORT COUNTRIES AND PEOPLE MOST IN NEED 3
750,000
THE NUMBER OF GLOBAL CITIZEN ACTIONS JOHNSON & JOHNSON SUPPORTED WHICH CONTRIBUTED TO DELIVERING $706M OF PLEDGES BY COUNTRIES AND COMPANIES  ACROSS THE GLOBE 3
 
IN THE NEWS
This year at BIO 2017, Johnson & Johnson announced new collaborations to accelerate the discovery of potential new treatments for tuberculosis, malaria, neglected tropics diseases and other diseases prevalent in the developing world.  Through WIPO Re:Search, the international research consortium led by the nonprofit BIO Ventures for Global Health and the United Nations World Intellectual Property Organization, Janssen Pharmaceutica NV has opened parts of its molecule library - containing a set of 80,000 diverse, high-quality compounds - to the global research community to enable collaborators to identify and advance promising drug candidates.
Robert Newman, MD, MPH, Global Head of TB Programs for Global Public Health at Johnson & Johnson spoke at the National Academies of Sciences, Engineering, and Medicine Forum on Microbial Threats on June 21-22 to discuss the challenge of microbial threats specifically in the fight against TB. During his panel, Dr. Newman explained how efforts by partners around the world to end TB as a health threat may provide a blueprint for how cross-sector partnerships can combat antimicrobial resistance. 
Hanneke Schuitemaker, Head of Viral Vaccines at Johnson & Johnson was joined on stage at Global Citizen by Dr. Soka Moses, a physician from Liberia who treated thousands of Ebola patients.
G20 Summit and Global Citizen Festival: 
We Want the World to be Ready 
Earlier this month, Jeremy Farrar, Director of Wellcome, and Paul Stoffels, Chief Scientific Officer of  Johnson & Johnson, urged world leaders attending the G20 Summit to keep up the momentum in tackling infectious disease outbreaks.  The call to share in their determination was met with several pledges by G20 leaders for global health problems including infectious disease outbreaks and the rise of drug-resistant infections.  These promises, shared by the global community, welcome the opportunity for rapid progress to prevent and contain epidemics, and protect the health of millions.

Ahead of G20, Johnson & Johnson shared its dedication to fighting global threats such as Ebola, HIV, TB and Zika with thousands of global citizens at the Global Citizen Festival in Germany . As part of that commitment, we  pledged  to maintain a stockpile of two million Ebola vaccine doses, to be deployed at any moment, to support those countries and people who need it the most. 
Anil Koul, Ph.D. is the new director of India's  Institute of Microbial Technology  (IMTECH). Taking leave from his role as Senior Director and Head of Respiratory Infections Discovery at the  Janssen Pharmaceutical Companies  of Johnson & Johnson, Dr. Koul is focused on tackling neglected tropical mosquito-borne viruses, like  dengue fever  and chikungunya.
As part of its commitment to make HIV history, 
Johnson & Johnson will be presenting its latest research advancements in HIV at the  9th International AIDS Society (IAS) Conference on HIV Science on July 23-26 in Paris, France. Alongside our partners, data on promising therapeutic innovations will be presented as well as an update on the development of its preventive HIV vaccine. To learn more, find all the latest at www.jnj.com/hiv. 
UPCOMING EVENTS

9th IAS Conference on HIV Science

July 23-26
Paris, France

Follow the conversation: #IAS2017
SOME OF THE KEY PRESENTATIONS YOU'LL FIND US AT: 
Monday, July 24
  • Symposia session: Translational Vaccinology 11:15 AM CEST, Room 251
  • Poster presentation: Pooled Efficacy Analysis of Two Phase III Trials of Dapivirine Vaginal Ring (DVR) for the Reduction of HIV-1 Infection Risk in HIV Uninfected Women in Sub-Saharan Africa, 12:30 PM CEST, Late Breaker Poster area Level 2
  • Oral abstract: Safety and Efficacy of Long-acting CAB and RPV as Two Drug IM Maintenance Therapy: LATTE2 Week 96 Results, Noon CEST, Blue Ampitheater 
Tuesday, July 25
  • Oral presentation: An open-label multiple dose Phase 1 assessment of long-acting rilpivirine, 11:30 AM CEST, Blue Amphitheater 
  • Oral presentation: Efficacy and safety of switching from boosted-protease inhibitor plus emtricitabine/ tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (D/C/F/TAF) in virologically-suppressed, HIV-1-infected adults through 24 weeks: EMERALD study, 2:30 PM CEST, Le Grand Amphithéâtre
  • Poster session: Sub-study 202094 of SWORD 1 & SWORD 2: switch from TDF containing regimen to DTG+RPV improves bone mineral density and bone turnover markers over 48 weeks, 1:20 PM CEST, Havana Ampitheater 
Wednesday, July 26
  • Poster session: Bioequivalence of a darunavir-based single-tablet complete HIV-1 regimen compared to the separate agents, 12:30 PM CEST, Poster Exhibition Area 
For more, visit   jnj.com/global-public-health